Nouvelle-Zélande - anglais - Medsafe (Medicines Safety Authority)

leo pharma limited - betamethasone dipropionate 643 µg/g equivalent to 500 µg/g betamethasone;  ; calcipotriol 50 µg/g (as calcipotriol hydrate 52.2µg/g) - topical ointment - 50µg/500µg/g - active: betamethasone dipropionate 643 µg/g equivalent to 500 µg/g betamethasone   calcipotriol 50 µg/g (as calcipotriol hydrate 52.2µg/g) excipient: ceteareth-15 dl-alpha tocopherol liquid paraffin white soft paraffin

Nouvelle-Zélande - anglais - Medsafe (Medicines Safety Authority)

leo pharma limited - betamethasone dipropionate 643 µg/g equivalent to 500 µg/g betamethasone;  ; calcipotriol monohydrate 52.2 µg/g equivalent to 50 µg/g calcipotriol - foam - active: betamethasone dipropionate 643 µg/g equivalent to 500 µg/g betamethasone   calcipotriol monohydrate 52.2 µg/g equivalent to 50 µg/g calcipotriol excipient: butane liquid paraffin methyl ether polyoxypropylene monostearyl ether tocoferols white soft paraffin - topical treatment of psoriasis vulgaris in adults.

Australie - anglais - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - calcipotriol, quantity: 52.2 microgram/g; betamethasone dipropionate, quantity: 643 microgram/g (equivalent: betamethasone, qty microgram/g) - ointment - excipient ingredients: dl-alpha-tocopherol; oleyl alcohol; liquid paraffin; white soft paraffin - indicated for the once daily topical treatment of plaque-type psoriasis vulgaris amenable to topical therapy.

Australie - anglais - Department of Health (Therapeutic Goods Administration)

freyr australia pty ltd - betamethasone dipropionate, quantity: 643 microgram/g (equivalent: betamethasone, qty 500 microgram/g); calcipotriol monohydrate, quantity: 52.2 microgram/g - foam - excipient ingredients: propane; polyoxypropylene-11 stearyl ether; isobutane; d-alpha-tocopherol; isopropyl alcohol; butane; white soft paraffin; liquid paraffin - topical treatment of psoriasis vulgaris in adults.

Australie - anglais - Department of Health (Therapeutic Goods Administration)

leo pharma pty ltd - calcipotriol, quantity: 50 microgram/g; betamethasone dipropionate, quantity: 643 microgram/g (equivalent: betamethasone, qty 500 microgram/g) - ointment - excipient ingredients: liquid paraffin; polyoxypropylene-11 stearyl ether; dl-alpha-tocopherol; white soft paraffin; butylated hydroxytoluene - daivobet ointment is indicated for the once daily topical treatment of plaque-type psoriasis vulgaris amenable to topical therapy.

États-Unis - anglais - NLM (National Library of Medicine)

actavis pharma, inc. - betamethasone dipropionate (unii: 826y60901u) (betamethasone - unii:9842x06q6m) - betamethasone 0.5 mg in 1 g - betamethasone dipropionate cream is a medium-potency corticosteroid indicated for relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses in patients 13 years and older. betamethasone dipropionate cream is contraindicated in patients who are hypersensitive to betamethasone dipropionate, to other corticosteroids, or to any ingredient in this preparation.

États-Unis - anglais - NLM (National Library of Medicine)

preferred pharmaceuticals, inc - betamethasone dipropionate (unii: 826y60901u) (betamethasone - unii:9842x06q6m) - betamethasone 0.5 mg in 1 g - betamethasone dipropionate ointment is a high-potency corticosteroid indicated for relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses in patients 13 years and older. betamethasone dipropionate ointment is contraindicated in patients who are hypersensitive to betamethasone dipropionate, to other corticosteroids, or to any ingredient in these preparations.

États-Unis - anglais - NLM (National Library of Medicine)

actavis pharma, inc. - betamethasone dipropionate (unii: 826y60901u) (betamethasone - unii:9842x06q6m) - betamethasone 0.5 mg in 1 g - betamethasone dipropionate ointment is a high-potency corticosteroid indicated for relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses in patients 13 years and older. betamethasone dipropionate ointment is contraindicated in patients who are hypersensitive to betamethasone dipropionate, to other corticosteroids, or to any ingredient in these preparations.

États-Unis - anglais - NLM (National Library of Medicine)

taro pharmaceuticals u.s.a., inc. - betamethasone dipropionate (unii: 826y60901u) (betamethasone - unii:9842x06q6m) - betamethasone dipropionate 0.64 mg in 1 g - betamethasone dipropionate cream is a medium-potency corticosteroid indicated for relief of the inflammatory and pruritic manifestations of corticosteroid responsive dermatoses in patients 13 years and older. betamethasone dipropionate cream is contraindicated in patients who are hypersensitive to betamethasone dipropionate, to other corticosteroids, or to any ingredient in this preparation.

États-Unis - anglais - NLM (National Library of Medicine)

e. fougera & co. a division of fougera pharmaceuticals inc. - betamethasone dipropionate (unii: 826y60901u) (betamethasone - unii:9842x06q6m) - betamethasone .50 mg in 1 g - betamethasone dipropionate gel (augmented) is a super-high potency corticosteroid indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. treatment beyond two consecutive weeks is not recommended, and the total dose should not exceed 50 g per week because of potential for the drug to suppress the hypothalamic-pituitary-adrenal (hpa) axis. this product is not recommended for use in pediatric patients under 12 years of age. betamethasone dipropionate gel (augmented) is contraindicated in those patients with a history of hypersensitivity to any of the components of the preparation.